Showing results (411-420 of 427) with videos related to
Sort By:
Pageof 43
The Lancet. Oncology|March 1, 2023
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trialSara M Tolaney, Paolo Tarantino, Noah Graham, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2016
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Breast Cancer Version 2.2015William J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2015
NCCN Guidelines Insights Breast Cancer, Version 1.2016William J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2022
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast CancerJonathan H Shepherd, Karla Ballman, Mei-Yin C Polley, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 10, 2012
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelinesRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Breast cancer, version 3.2013: featured updates to the NCCN guidelinesRichard L Theriault, Robert W Carlson, Craig Allred, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramF Cardoso, J M S Bartlett, L Slaets, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2014
Breast cancer version 3.2014William J Gradishar, Benjamin O Anderson, Sarah L Blair, et al.Nature Cancer|September 1, 2020
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitorsPedram Razavi, Maura N Dickler, Payal D Shah, et al.Pageof 43